Canakinumab
- Generic Name
- Canakinumab
- Brand Names
- Ilaris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914613-48-2
- Unique Ingredient Identifier
- 37CQ2C7X93
- Background
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain ...
- Indication
Canakinumab is indicated for the treatment of periodic fever syndromes in specific patient populations. In patients ≥4 years of age, canakinumab is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). In adult and pediatric patients, canakinum...
- Associated Conditions
- Adult Onset Still's Disease, Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS), Familial Mediterranean Fever (FMF ), Gout Flares, Mevalonate Kinase Deficiency, Muckle-Wells Syndrome (MWS), Systemic Juvenile Idiopathic Arthritis (SJIA), Tumour necrosis factor receptor-associated periodic syndrome
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.